These findings present a promising direction for screening potential agents that can enhance the effectiveness of the PFKFB3/PFK pathway, thereby benefiting the clinical treatment of retinal barrier disorders associated with endothelial dysfunction. The gene discussed is PFKFB3; the disease is endothelial dysfunction.